Endo pulls Frova app after mulling FDA response

Endo Pharmaceuticals says a close reading of a non-approvable letter from the FDA for Frova prompted officials to pull their request to gain approval for the short-term relief of menstrual migraine. The Chadds Ford, PA-based developer has already won approval for the use of Frova against acute migraine for patients with a clear diagnosis. And without explanation Endo says it will return the rights to Chronogesic to Durect.

"The decision to withdraw the unapproved supplemental application was complex; however, after a lengthy and detailed evaluation of the points raised in the FDA 'not approvable' letter, we have determined the withdrawal to be the appropriate course of action at this time," said Endo CEO Dave Holveck (photo).

- here's the release
- read the report in the Philadelphia Business Journal

Related Articles:
Endo, Vernalis get FDA rejection for Frova. Report
Endo plans for the future. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.